Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Semaglutide & Type 2 Diabetes (T2D)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Concerning Semaglutide & Type 2 Diabetes (T2D), both FDA and EMA have approved semaglutide for the treatment of adults with type 2 diabetes, in both injectable and oral formulations (1, 2).

Clinical data

In the randomized, double-blind, double-dummy, placebo-controlled clinical phase III treatment trial known as NCT03552757 (STEP 2), it was found

that adults who are overweight or obese and have type 2 diabetes experienced a significant and clinically meaningful reduction in body weight when treated with semaglutide 2.4 mg once a week, compared to those who received a pl…

References (Sources)

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain et al. 2019 N Engl J Med 381: 841-851
Oral semaglutide vs subcutaneous liraglutide & placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase IIIa trial
Pratley et al. 2019 Lancet 394: 39-50
Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
Andersen et al. 2021 Drugs 81(9): 1003-1030
Review
Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy
Gomez-Peralta et al. 2019 Drug Des Devel Ther 13: 731-738
Review
Semaglutide 2.4 mg once a week in adults with overweight or adiposity/obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase III trial
Davies et al., 2021 Lancet 397: 971-984
Semaglutide for the treatment of overweight and obesity: A review
Bergmann et al. 2023 Diabetes Obes Metab 25(1): 18-35
Review

AI Chat

7/1/2026

Chat with our artificial intelligence: